Trial Profile
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Dec 2019
Price :
$35
*
At a glance
- Drugs Florbetapir F 18 (Primary)
- Indications Alzheimer's disease
- Focus Diagnostic use
- Sponsors Genentech
- 19 Dec 2019 Status changed from active, no longer recruiting to completed.
- 09 Apr 2019 Planned End Date changed from 31 May 2019 to 11 Jun 2019.
- 09 Apr 2019 Planned primary completion date changed from 31 May 2019 to 11 Jun 2019.